British National Formulary March 2024 Update
This update contains 5 significant changes, 1 dose change, 4 new monographs and 2 deleted monographs.
Significant Changes:
Aripiprazole (Abilify® and generic brands): risk of pathological gambling [MHRA/CHM advice].
Empagliflozin: update to advice on use in renal impairment, including new indication for chronic kidney disease.
Quinolones: must now only be prescribed when other commonly recommended antibiotics are inappropriate [MHRA/CHM advice] (see example in ciprofloxacin).
Type 2 diabetes: updated guidance for management.
Vitamin B12: advise patients with known cobalt allergy to be vigilant for sensitivity reactions [MHRA/CHM advice] (advice in cyanocobalamin, hydroxocobalamin; see example in hydroxocobalamin).
Dose Changes:
- Secukinumab [update to dosing for psoriatic arthritis with concomitant moderate to severe plaque psoriasis].
New Monographs:
- Inaqovi® [decitabine with cedazuridine].
- Litfulo® [ritlecitinib].
- Livmarli® [maralixibat].
- Veoza® [fezolinetant].
Deleted Monographs: Cinchocaine hydrochloride with fluocortolone caproate and fluocortolone pivalate; Simvastatin with fenofibrate.